Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Differentiating between indolent and aggressive prostate cancers (CaP) is important to decrease overtreatment and increase survival for men with aggressive disease. Nucleolar prominence is a histologic hallmark of CaP; however, the expression, localization, and functional significance of specific nucleolar proteins have not been investigated thoroughly. The nucleolar protein
block of proliferation 1
(
BOP1
) has been associated with multiple cancers but has not been implicated previously in CaP. Meta-analysis of publicly available data showed increased
BOP1
expression in metastatic CaP, recurrent CaP, and was inversely associated with overall survival. Multiplexed immunohistochemistry was used to analyze expression and localization of
BOP1
and nucleolar marker NOP56 in human tissue samples from various stages of CaP progression. Here, increased
BOP1
expression was observed at later stages of CaP progression, coinciding with a localization change from nuclear to cytoplasmic. In patient samples, cytoplasmic
BOP1
was also inversely associated with overall survival. In models of
prostate cancer
progression,
BOP1
expression showed similar expression and localization to human patient samples. The functional significance of
BOP1
in metastatic CaP was assessed by genetic knockdown, where
BOP1
knockdown resulted in decreased proliferation and motility compared with control. Taken together, these data suggest prognostic significance of
BOP1
expression and localization in CaP progression and provide a foundation for further investigation into the functional role of nucleolar proteins in advanced CaP.
...
PMID:Expression, Localization, and Function of the Nucleolar Protein BOP1 in Prostate Cancer Progression. 3303 51
